ClinicalTrials.gg
Not yet recruitingNCT07854795RELEASE-NorwayUpdated Nov 9, 2026

Reconsidering Long-Term Apirin in the Elderly in Secondary Prevention of Coronary Artery Disease Norway

A Phase 4 interventional study of Discontinuation of aspirin (ATC-code B01AC06 and N02BA01) in Coronary Arterial Disease (CAD), sponsored by Vestre Viken Hospital Trust. Not yet recruiting at 9 sites in Norway. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Vestre Viken Hospital Trust · Phase 4, Interventional, and Treatment

How we know

Updated Nov 9, 2026Primary outcomes revisedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
7,000
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

Lifelong aspirin has been a cornerstone of secondary prevention after coronary artery disease (CAD), based on trials conducted 40-50 years ago. Since then, major advances in coronary reperfusion and risk factor management have significantly improved outcomes. At the same time, aspirin is clearly associated with an increased risk of major bleeding, including intracranial haemorrhage. This raises a critical, yet unanswered question: in patients more than 2 years after a CAD event, does the benefit of continued aspirin still outweigh its bleeding risk? RELEASE-Norway is an investigator-initiated, registry-based, randomised trial with blinded endpoint assessment (PROBE design) designed to determine whether patients with chronic CAD can safely stop aspirin without losing cardiovascular protection. The trial will randomise 7,000 patients from all major hospitals in Norway. Together with a similar trial (RELEASE-Denmark, n≈7,000) planned in Denmark, the study will provide definitive evidence on the long-term net clinical benefit versus harm of aspirin in stable CAD and most likely directly inform future guidelines and clinical practice worldwide. Imaging and PROMS sub-studies will explore clinical and psychosocial mechanisms, providing insight into treatment heterogeneity and enabling future personalised antiplatelet therapy. Additionally, a health-economic analysis will assess the cost-effectiveness of discontinuing aspirin for healthcare systems.

02

Conditions studied

  • Coronary Arterial Disease (CAD)

Keywords

  • RELEASE
  • Aspirin
  • PCI
03

In context

Lead sponsor

Vestre Viken Hospital Trust is the lead sponsor of 52 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥65 years at randomization treated with low-dose (≤150 mg/day) aspirin
  • An ACS event treated with PCI 2-8 years prior to randomisation and no ischemic cardiovascular event (MI or stroke) or any coronary revascularization procedure (PCI/coronary artery bypass grafting) since index event
  • Signed and expected cooperation according to ICH/GCP and national/local regulations

Exclusion criteria

Exclusion Criteria:

  • Indication for antiplatelet treatment other than secondary prevention of CAD (i.e. haematological diseases, stroke, PAD)
  • Active treatment with or indication for anti-coagulant or P2Y12-inhibitor therapy
  • Left main stenosis or any history of stent thrombosis, or other to discontinuation of aspirin according to treating physician
  • Any condition (e.g. drug/alcohol abuse, dementia) or situation, that in the investigator's opinion could put the subject at signifi-cant risk directly related to the randomized aspirin strategy, confound the results, interfere significantly with participation, or render unfeasible. Investigators are explicitly encouraged not to exclude patients solely due to advanced age, frailty or polypharmacy if equipoise exists regarding aspirin continuation vs. discontinuation and informed consent is feasible.
  • \<12 months due to non-cardiac reasons or not being able to understand Norwegian or English language
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
7,000 participants (estimated)

Study arms

  • Experimental
    Aspirin discontinuation

    Patients in the intervention group will be randomized to discontinuing aspirin treatment. The drug will be discontinued from their medical list. All participants will receive lifestyle advice and appropriate follow-up, as recommended.

    Drug: Discontinuation of aspirin (ATC-code B01AC06 and N02BA01)

  • No intervention
    Aspirin continuation (ATC-codes B01AC06 and N02BA01)

    Patients will be randomized to continuation of of low-dose oral aspirin (Anatomical Therapeutic Chemical codes B01AC06 and N02BA01) at a daily dose of ≤150 mg (usual care, no intervention). All participants will receive lifestyle advice and appropriate follow-up, as recommended.

Interventions

  • DrugDiscontinuation of aspirin (ATC-code B01AC06 and N02BA01)

    Patients will be randomized open-label 1:1 to either continuation of low-dose oral aspirin (Anatomical Therapeutic Chemical codes B01AC06 and N02BA01) at a daily dose of ≤150 mg (no intervention group) or discontinuation of aspirin therapy (intervention group). If the patient is randomized to discontinuing aspirin the treatment will be discontinued from their medical list. All participants will receive lifestyle advice and appropriate follow-up, as recommended.

06

What researchers measure

Primary outcomes

  1. Hierarchical composite endpont

    The net clinical benefit of discontinuing versus continuing aspirin in patients randomized 2-8 years after an index ACS event, using a hierarchical composite endpoint with a win-ratio framework that includes: 1. Cardiovascular death, 2. Fatal bleedings, 3. Intracranial bleeding, 4. Myocardial infarctions including stent thrombosis, 5. Ischemic stroke, 6. Major bleeding (BARC 3 and 5) requiring hospitalization. The components of the endpoints will be identified in The Norwegian Patient Registry and Cause of Death Registry using procedure and diagnostic codes.

    Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up

Secondary outcomes

  1. Risk of ischaemic disease

    The cumulative risk of a composite of recurrent myocardial infarction including stent thrombosis, ischemic stroke, and cardiovascular death by randomization group. Events will be identified in the Norwegian Patient Registry and the Norwegian Cause of Death registry using procedure and diagnostic codes.

    Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up

  2. Risk of major bleedings

    The cumulative risk of major bleedings, including intracranial and other major (BARC 3, 5) bleeding events requiring hospitalization by randomization group. Events will be identified in The Norwegian Patient Registry and the Cause of Death registry data with procedure and diagnostic codes.

    Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up

Other outcomes

  1. Subgroup analyses

    The net clinical benefit of discontinuing versus continuing aspirin across subgroups by age, sex, Clinical Frailty Scale score \<4 vs. ≥4 (mild frailty), single vs. multi-vessel disease, and discontinuation 2-4 years vs. 4-8 years after index event. The net clinical benefit will be analyzed the same way as for the primary endpoint: a win-ratio framework using a hierarchical composite endpoint including both ischemic events and major bleeding events.

    Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up

  2. Risk of individual components of the primary endpoint

    The cumulative risk of the individual components of the primary endpoint by randomization group. Events will be identified in The Norwegian Patient Registry and The Norwegian Cause of Death Registry using procedure and diagnostic codes.

    Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up

  3. Recurrent CVD hospitalisations

    The cumulative risk of recurrent hospitalization for (any) cardiovascular disease by randomization status. Hospitalizations will be identified in registry data using diagnostic and procedure codes.

    Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up

  4. All-cause mortality

    The cumulative risk of all-cause mortality by randomization group. All-cause mortality will be obtained from the Cause of Death Registry

    Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up

  5. Major and minor bleedings

    Cumulative risk of major or minor bleedings (BARC 2,3,5) Minor bleedings will be assessed using 10 questions based on the International Society on Thrombosis and Haemostasis (ISTH) bleeding assessment approach. Major bleedings will be identified in the Norwegian Patient registry using diagnostic and procdedure codes.

    Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up

  6. Gastrointestinal ulcer

    The cumulative risk of gastrointestinal ulcer by randomization group. Gastroinestinal ulcer is optained from both the Norwegian Patient registry and self-reported questionnaires.

    Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up

  7. Malignant diseases

    Cumulative risk of incident malignant diseas by randomization group. Malignant disease will be obtained from the Cancer Registry of Norway.

    Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up

  8. Adherence to allocated treatment

    Adherence to allocated treatment evaluated by redeemed prescriptions at the pharmacy. Obtained from The Norwegian Prescription Database.

    Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up

  9. Health economics

    Cost-utilty analysis in relation to quality of life and a healthcare utilization by randomization group. Quality of life will be obtained by the EQ-5D questionnaire and healthcare utilization will be obtained from The Norwegian Patient Registry.

    Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up

  10. Changes in quality of life

    Changes in quality of life by randomization group measured by EQ-5D questionnaire

    Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up

  11. Changes in lifestyle factors

    Changes in lifestyle behaviour by randomization group measured by the NORCOR Lifestyle Questionnaire. The NORCOR lifestyle questionnaire includes queestions on smoking status and quitting motiviation, alcohol consumption, physical activity and body weight and height. Smoking status: never, former, current Physical activity: Assessed by a validated questionnaire form HUNT1 which assesses frequency (never, \<once/week, once/week, two to three times/week and almost every day), intensity (light, medium and vigorous), and duration (\<15 minutes (min), 15-29 min, 30-60 min, and \>60 min) Body weight and height: Self-report body weight and height Alcohol consumption: Average number of units of alcohol consumed per week

    Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up

  12. Changes in angina symptoms

    Changes in angina symptoms by randomization group measured by the Seattle Angina Questionnaire. The Seattle Angina Questionnaire is a validated 7-item questionnaire assessing angina frequency, symptom burden, physical limitation, and quality of life related to coronary artery disease. The summary score ranges from 0-100 and higher scores indicate better functioning, fewer physical limitations, less frequent angina, and a higher quality of life.

    Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up

  13. Origin of recurrent ischemic events

    Risk of recurrent ischemic events by origin (previously treated PCI lesion or progression of CAD in non-target segments) and by randomization group. Information will be obtained from hospital medical records upon hospitalization for a reccurent event (a subgroup assessed by FFR/OCT) and from registry data (The Norwegian Registry of Invasive Cardiology and The Norwegian Patient Registry).

    Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up

  14. Patient-reported anxiety

    Changes in patient-reported anxiety by randomization group using the Generalized Anxiety Disorder-2 (GAD-2) questionnaire. The total score ranges from 0-6 and a score of 3 or higher is considered a positive screen for anxiety

    Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up

  15. Patient reported depression

    Changes in patient reported depression by randomization group measured by the Patient Health Questionnaire-2 (PHQ-2). Total score ranges from 0 to 6 and a score of 3 or higher is considered a positive screen for depression.

    Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up

  16. Patient-reported sleep disturbances

    Changes in patient reported sleep disturbance by randomization group measured by Bergen Insomnia Scale (BIS). BIS is a validated questionnaire used to assess insomnia symptoms and sleep difficulties based on diagnostic criteria for insomnia, including sleep onset, sleep maintenance, early awakening, and daytime impairment. The Bergen Insomnia Scale (BIS) has a minimum score of 0, a maximum score of 42, and a diagnostic cutoff requiring a score of 3 or higher on at least one of the first four items (nighttime symptoms) combined with 3 or higher on at least one of the last two items (daytime consequences/dissatisfaction).

    Time frame: From randomization to median 3.0 (minimum 1.0) years follow-up

07

Study locations

9 sites
08

References and documents

Individual participant data

Plan to share: No — Individual participant-level data cannot be made publicly available due to data protection regulations and applicable Norwegian legislation.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2027; primary completion for Dec 2030, 46 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Oct 2, 2026
StartEst.
Feb 1, 2027
Primary completionEst.
Dec 1, 2030
CompletionEst.
Dec 1, 2031
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionHierarchical composite endpont: how it is measured was reworded
Nov 9, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 2 updates
  1. Nov 9, 2026
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionHierarchical composite endpont: how it is measured was reworded
    + 1 other change: verification date
  2. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07854795
Lead sponsor
Vestre Viken Hospital Trust
Collaborators
Oslo Universitetssykehus Hospital Trust, Akershus University Hospital Trust, Sorlandet Hospital HF, Helse Stavanger HF, Helse-Bergen HF, St. Olavs Hospital, Norwegian Health Association, Landsforeningen for hjerte og lungesyke (LHL), Bispebjerg Hospital, Odense University Hospital, University of Oslo, University Hospital of North Norway
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Feb 1, 2027 (estimated)
Primary completion
Dec 1, 2030 (estimated)
Completion
Dec 1, 2031 (estimated)
Last update
Nov 9, 2026

Study contacts

John Munkhaugen, MD, PhD
Contact
johmun@vestreviken.no
+47 97524194
Ingrid Engebretsen, PhD
Contact
engebi@vestreviken.no
+4794406413
John Munkhaugen, MD, PhD
principal investigator · Vestre Viken HF

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion